Our CSO Agapitos joined RoukenBio in 2018. He originally trained as a pharmacist, followed by an MSc in Immuno-Pharmacology & MPhil in Pharmacology (Uni of Strathclyde) and a PhD in Immunology/Rheumatology (Uni of Glasgow). As a post-doctoral researcher in the Institute of Infection, Immunity & Inflammation he specialised in the role of T cells in inflammatory arthritis and published several papers on the subject.
In 2015, he moved to industry focusing on the development of T cell therapies against cancer. There he led process and product development activities, established CAR-T programs and had a critical role in securing several millions of non-dilutive funding.
Agapitos then joined RoukenBio, where he established the translational immunology business unit, leading the development of several bespoke immunology assays such as our T cell exhaustion, T-cell mediated cytotoxicity assays etc., significantly expanding the company’s service portfolio.
In 2020, Agi became CSO and now strategically leads all R&D and new service development. He is co-inventor in several patents in the field of T cell therapies and cell line development.
Resources
Research Posters
17 August 2026
|4 min read
This research poster presents a high-throughput, patient-derived colorectal cancer tumoroid platform incorporating autologous fibroblasts and tumour-infiltrating lymphocytes. By combining genomic, gene-expression and drug-response data, the model captures patient-specific tumour heterogeneity and supports translational drug discovery, predictive biomarker identification and immunotherapy research.
Research Posters
22 October 2025
|4 min read
Antigen-specific T cells are essential for evaluating immune-modulating therapies, but sourcing them for research is challenging. This blog highlights the development of ‘Thaw & Go’ transgenic TCR-T cell banks and methods to expand endogenous antigen-specific T cells, providing ready-to-use resources for high-throughput assessment of immune modulators and advancing drug discovery efforts.
Research Posters
27 June 2025
|6 min read
The advancement of immunotherapies, including CAR-T cell treatments, has driven a growing need for more predictive preclinical models. Addressing this, RoukenBio and ScreenIn3D have partnered to deliver next-generation 3D in vitro platforms that better replicate the tumour microenvironment.
